Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Gross Profit (2022 - 2025)

Historic Gross Profit for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to -$100088.0.

  • 60 Degrees Pharmaceuticals' Gross Profit fell 52399.39% to -$100088.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $164631.0, marking a year-over-year increase of 10925.45%. This contributed to the annual value of $222809.0 for FY2024, which is 20082.9% up from last year.
  • Latest data reveals that 60 Degrees Pharmaceuticals reported Gross Profit of -$100088.0 as of Q3 2025, which was down 52399.39% from $50881.0 recorded in Q2 2025.
  • Over the past 5 years, 60 Degrees Pharmaceuticals' Gross Profit peaked at $123558.0 during Q4 2024, and registered a low of -$200009.0 during Q4 2022.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' median Gross Profit value was $1799.0 (recorded in 2023), while the average stood at -$8796.2.
  • In the last 5 years, 60 Degrees Pharmaceuticals' Gross Profit surged by 70049.57% in 2024 and then plummeted by 52399.39% in 2025.
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' Gross Profit stood at -$200009.0 in 2022, then skyrocketed by 89.71% to -$20576.0 in 2023, then skyrocketed by 700.5% to $123558.0 in 2024, then crashed by 181.0% to -$100088.0 in 2025.
  • Its Gross Profit stands at -$100088.0 for Q3 2025, versus $50881.0 for Q2 2025 and $90280.0 for Q1 2025.